碘对比剂诱发甲状腺功能减退的病因及临床特点研究进展

doi:10.11958/20220392

天津医药 ›› 2022, Vol. 50 ›› Issue (11): 1222-1226.doi: 10.11958/20220392

碘对比剂诱发甲状腺功能减退的病因及临床特点研究进展

韩楚仪¹(), 张敬霞², 丛洪良²^,^△()

1 天津医科大学胸科临床学院（邮编300222）
2 天津市胸科医院心内八科

收稿日期:2022-03-17 修回日期:2022-05-28 出版日期:2022-11-15 发布日期:2022-11-11
通讯作者: 丛洪良 E-mail:402124067@qq.com;hongliangcong@126.com
作者简介:韩楚仪（1993），女，博士在读，主要从事心血管疾病方面研究。E-mail：402124067@qq.com
基金资助:
天津市科技计划项目(17ZXMFSY00020)

Research progress on etiology and clinical characteristics of ICM-induced hypothyroidism

HAN Chuyi¹(), ZHANG Jingxia², CONG Hongliang²^,^△()

1 Clinical School of Thoracic, Tianjin Medical University, Tianjin 300222, China
2 the Eighth Department of Cardiology, Tianjin Chest Hospital

Received:2022-03-17 Revised:2022-05-28 Published:2022-11-15 Online:2022-11-11
Contact: CONG Hongliang E-mail:402124067@qq.com;hongliangcong@126.com

韩楚仪, 张敬霞, 丛洪良. 碘对比剂诱发甲状腺功能减退的病因及临床特点研究进展[J]. 天津医药, 2022, 50(11): 1222-1226.

HAN Chuyi, ZHANG Jingxia, CONG Hongliang. Research progress on etiology and clinical characteristics of ICM-induced hypothyroidism[J]. Tianjin Medical Journal, 2022, 50(11): 1222-1226.

摘要/Abstract

摘要：

应用碘对比剂（ICM）可诱发甲状腺功能减退（IIHypo）。新近研究发现ICM可独立于游离碘而特异性抑制甲状腺对碘化物摄取，其作用机制与传统的Wolff-Chaikoff效应并不一致。目前关于IIHypo发病率、相关危险因素及监测ICM诱发事件的适应证等问题尚未完全确定。认识发生IIHypo的潜在风险因素、及时评估在碘暴露时间窗内发生的碘诱导事件，对优化ICM诱发甲状腺功能障碍诊断和管理程序具有重要临床意义。

关键词: 甲状腺功能减退症, 碘化造影剂, Wolff-Chaikoff效应, 风险因素

Abstract:

Iodinated contrast media (ICM) administration may induce hypothyroidism (IIHypo). Recent studies have found that ICM can specifically inhibit thyroid iodide uptake by iodide independently of free iodide through a mechanism different from the conventional Wolff-Chaikoff effect. At present, issues regarding the incidence of IIHypo, related risk factors and indications for monitoring ICM-induced events have not been fully determined. Recognizing of potential risk factors for IIHypo and timely assessment of iodine-induced events within the time window of iodine exposure have important clinical significance for optimizing the diagnosis and management procedures of ICM-induced thyroid dysfunction.

Key words: hypothyroidism, iodinated contrast media, Wolff-Chaikoff effect, risk factors

中图分类号:

R541.4

图/表 1

参考文献 35

[1]	BEDNARCZUK T, BRIX T H, SCHIMA W, et al. 2021 European Thyroid Association guidelines for the management of iodine-based contrast media-induced thyroid dysfunction[J]. Eur Thyroid J,2021, 10(4):269-284. doi:10.1159/000517175.
[2]	BELLONI E, TENTONI S, PUCI M V, et al. Effect of iodinated contrast medium on thyroid function:A study in children undergoing cardiac computed tomography[J]. Pediatr Radiol, 2018, 48(10):1417-1422. doi:10.1007/s00247-018-4163-3.
[3]	HICHRI M, VASSAUX G, GUIGONIS J M, et al. Proteomic analysis of iodinated contrast agent-induced perturbation of thyroid iodide uptake[J]. J Clin Med, 2020, 9(2):329.doi:10.3390/jcm9020329.
[4]	JICK S S, HEDDERSON M, XU F, et al. Iodinated contrast agents and risk of hypothyroidism in young children in the United States[J]. Invest Radiol, 2019, 54(5):296-301. doi:10.1097/RLI.0000000000000541.
[5]	LEIDIG-BRUCKNER G. Iodinated contrast medium in patients with thyroid disorders[J]. Radiologe, 2019, 59(5):413-424. doi:10.1007/s00117-019-0520-y.
[6]	BØHMER T, BACHTYARI Z, SOMMER C, et al. Auto regulatory capacity of the thyroid gland after numerous iodinated contrast media investigations[J]. Scand J Clin Lab Invest, 2020, 80(3):191-195. doi:10.1080/00365513.2019.1709658.
[7]	MARTENS B, HENDRIKS B, EIJSVOOGEL N G, et al. Individually body weight-adapted contrast media application in computed tomography imaging of the liver at 90 kVp[J]. Invest Radiol, 2019, 54(3):177-182. doi:10.1097/RLI.0000000000000525.
[8]	VASSAUX G, ZWARTHOED C, SIGNETTI L, et al. Iodinated contrast agents perturb iodide uptake by the thyroid independently of free iodide[J]. J Nucl Med, 2018, 59(1):121-126. doi:10.2967/jnumed.117.195685.
[9]	ÜREYEN Ç M, COŞANSU K, VURAL M G, et al. Percutaneous coronary intervention for chronic total occlusion versus percutaneous coronary intervention for non-complex coronary lesions:Is there a different impact on thyroid function?[J]. Med Princ Pract, 2020, 29(2):188-194. doi:10.1159/000503553.
[10]	KAHALY G J, DIANA T, OLIVO P D. TSH receptor antibodies: Relevance & utility[J]. Endocr Pract, 2020, 26(1):97-106. doi:10.4158/EP-2019-0363.
[11]	RESENDE M, CORBO R, VAISMAN M. The effect of recombinant human TSH on ¹²³I thyroid uptake after intravenous iodide contrast agent[J]. Nucl Med Commun, 2010, 31(4):315-319. doi:10.1097/MNM.0b013e3283355c8b.
[12]	BONELLI N, ROSSETTO R, CASTAGNO D, et al. Hyperthyroidism in patients with ischaemic heart disease after iodine load induced by coronary angiography:Long-term follow-up and influence of baseline thyroid functional status[J]. Clin Endocrinol (Oxf), 2018, 88(2):272-278. doi:10.1111/cen.13494.
[13]	SI H L, QIN Q, LIU Y Y, et al. No longterm severe thyroid dysfunction seen in patients with preexisting reduced serum Tt3 concentrations after a single large dose of iodinated contrast[J]. Endocr Pract, 2020, 26(8):840-845. doi:10.4158/EP-2019-0600.
[14]	BARR M L, CHIU H K, LI N, et al. Thyroid dysfunction in children exposed to iodinated contrast media[J]. J Clin Endocrinol Metab, 2016, 101(6):2366-2370. doi:10.1210/jc.2016-1330.
[15]	BERVINI S, TRELLE S, KOPP P, et al. Prevalence of iodine-induced hyperthyroidism after administration of iodinated contrast during radiographic procedures:A systematic review and Meta-Analysis of the literature[J]. Thyroid, 2021, 31(7):1020-1029. doi:10.1089/thy.2020.0459.
[16]	VAN WELIE N, ROEST I, PORTELA M, et al. Thyroid function in neonates conceived after hysterosalpingography with iodinated contrast[J]. Hum Reprod, 2020, 35(5):1159-1167. doi:10.1093/humrep/deaa049.
[17]	KUBICKI R, GROHMANN J, KUNZ K G, et al. Frequency of thyroid dysfunction in pediatric patients with congenital heart disease exposed to iodinated contrast media -a long-term observational study[J]. J Pediatr Endocrinol Metab, 2020, 33(11):1409-1415. doi:10.1515/jpem-2020-0032.
[18]	SO S, YAMAGUCHI W, TAJIMA H, et al. The effect of oil and water-soluble contrast medium in hysterosalpingography on thyroid function[J]. Gynecol Endocrinol, 2017, 33(9):682-685. doi:10.1080/09513590.2017.1307960.
[19]	KORNELIUS E, CHIOU J Y, YANG Y S, et al. Iodinated contrast media-induced thyroid dysfunction in Euthyroid Nodular Goiter patients[J]. Thyroid, 2016, 26(8):1030-1038. doi:10.1089/thy.2016.0051.
[20]	GARTNER W, WEISSEL M. Do iodine-containing contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week?[J]. Thyroid, 2004, 14(7):521-524. doi:10.1089/1050725041517075.
[21]	KORNELIUS E, CHIOU J Y, YANG Y S, et al. Iodinated contrast media increased the risk of thyroid dysfunction:A 6-year retrospective cohort study[J]. J Clin Endocrinol Metab, 2015, 100(9):3372-3379. doi:10.1210/JC.2015-2329.
[22]	RAZVI S, JABBAR A, PINGITORE A, et al. Thyroid hormones and cardiovascular function and diseases[J]. J Am Coll Cardiol, 2018, 71(16):1781-1796. doi:10.1016/j.jacc.2018.02.045.
[23]	THAKER V V, GALLER M F, MARSHALL A C, et al. Hypothyroidism in infants with congenital heart disease exposed to excess iodine[J]. J Endocr Soc, 2017, 1(8):1067-1078. doi:10.1210/js.2017-00174.
[24]	徐佩, 关海霞. 胺碘酮和含碘造影剂致甲状腺功能障碍的机制和临床管理[J]. 医学综述, 2021, 27(14):2808-2813.
	XU P, GUAN H X. Mechanism and clinical management of thyroid dysfunction induced by amiodarone and iodinated contrast[J]. Medical Recapitulate, 2021, 27(14):2808-2813.doi:10.3969/j.issn.1006-2084.2021.14.019.
[25]	RUSANDU A, SJøVOLD B H, HOFSTAD E, et al. Iodinated contrast media and their effect on thyroid function - Routines and practices among diagnostic imaging departments in Norway[J]. J Med Radiat Sci, 2020, 67(2):111-118. doi:10.1002/jmrs.390.
[26]	LEE S Y, RHEE C M, LEUNG A M, et al. A review:Radiographic iodinated contrast media-induced thyroid dysfunction[J]. J Clin Endocrinol Metab, 2015, 100(2):376-383. doi:10.1210/jc.2014-3292.
[27]	HAN S, YOON S H, LEE W, et al. Management of adverse reactions to iodinated contrast media for computed tomography in korean referral hospitals:A survey investigation[J]. Korean J Radiol, 2019, 20(1):148-157. doi:10.3348/kjr.2017.0771.
[28]	ITTERMANN T, ALBRECHT D, AROHONKA P, et al. Standardized map of iodine status in Europe[J]. Thyroid, 2020, 30(9):1346-1354. doi:10.1089/thy.2019.0353.
[29]	WANG B, HE W, LI Q, et al. U-shaped relationship between iodine status and thyroid autoimmunity risk in adults[J]. Eur J Endocrinol, 2019, 181(3):255-266. doi:10.1530/EJE-19-0212.
[30]	BARTALENA L, BOGAZZI F, CHIOVATO L, et al. 2018 European Thyroid Association (ETA) guidelines for the management of Amiodarone-associated thyroid dysfunction[J]. Eur Thyroid J,2018, 7(2):55-66. doi:10.1159/000486957.
[31]	DOOST A, ALASADY M, SCOTT P. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand:Australian clinical guidelines for the diagnosis and management of Atrial Fibrillation 2018[J]. Heart Lung Circ, 2019, 28(5):e106-e107. doi:10.1016/j.hlc.2018.11.016.
[32]	BAJUK V, ZALETEL K, PIRNAT E, et al. Effects of adequate iodine supply on the incidence of iodine-induced thyroid disorders in Slovenia[J]. Thyroid, 2017, 27(4):558-566. doi:10.1089/thy.2016.0186.
[33]	RHEE C M. Thyroid disease in end-stage renal disease[J]. Curr Opin Nephrol Hypertens, 2019, 28(6):621-630. doi:10.1097/MNH.0000000000000542.
[34]	MALONEY E, IYER R S, PHILLIPS G S, et al. Practical administration of intravenous contrast media in children:Screening, prophylaxis, administration and treatment of adverse reactions[J]. Pediatr Radiol, 2019, 49(4):433-447. doi:10.1007/s00247-018-4306-6.
[35]	HSIEH M S, CHIU C S, CHEN W C, et al. Iodinated contrast medium exposure during computed tomography increase the risk of subsequent development of thyroid disorders in patients without known thyroid disease:A nationwide population-based, propensity score-matched, longitudinal follow-up study[J]. Medicine (Baltimore), 2015, 94(50):e2279. doi:10.1097/MD.00000000000 02279.

碘对比剂诱发甲状腺功能减退的病因及临床特点研究进展

Research progress on etiology and clinical characteristics of ICM-induced hypothyroidism

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 1

参考文献 35

相关文章 9

编辑推荐

Metrics

本文评价

[1]	韩楚仪, 丛洪良, 王乐, 张敬霞. NSTE-ACS患者应用碘对比剂后甲状腺功能减退的风险因素预测[J]. 天津医药, 2023, 51(4): 422-426.
[2]	王康, 徐卫国△, 董洪超, 贾纯亮, 丁梅, 董丽儒, 司瑞芬. 甲状旁腺腺瘤大小与甲状旁腺功能及甲状腺功能的相关性研究[J]. 天津医药, 2021, 49(3): 305-309.
[3]	夏晨曦, 魏东, 黄斌, 周正阳, 李宏宇. 亚临床甲状腺功能减退与内脏脂肪组织的相关性研究[J]. 天津医药, 2018, 46(9): 959-962.
[4]	明丹 , 郑荣秀 . 新生儿及母亲临床特征对先天性甲状腺功能减退症筛查的影响[J]. 天津医药, 2018, 46(7): 742-746.
[5]	舒雯, 刘映川, 张梅. 急性心肌梗死合并甲状腺功能减低患者的临床特征观察[J]. 天津医药, 2017, 45(11): 1167-1170.
[6]	刘映川，张梅. 亚临床甲状腺功能减退症与心血管疾病相关性的研究进展[J]. 天津医药, 2016, 44(4): 509-512.
[7]	单忠艳△. 妊娠期甲状腺功能减退症的诊治进展[J]. 天津医药, 2016, 44(11): 1297-1301.
[8]	苗莉 1，丁瑾 2，严庭智 2，刘迎午 1，姚小梅 2△. 亚临床甲状腺功能减退症合并心血管疾病患者的临床特征分析[J]. 天津医药, 2016, 44(11): 1308-1310.
[9]	刘春蓉1 ,于保国2 ,杨术旺2 ,刘燕青2 ,刘亚敏2 ,张永亮2 . 先天性甲状腺功能减退症大脑蛋白质双向电泳分析[J]. , 2010, 38(6): 0-0 .